Macau Fast-Track Regulatory Pathway into Mainland China Deflazacort (known as Emflaza in the U.S.) was introduced to China through an innovative regulatory route leveraging Macau’s fast-track approval system. ACA Pharma spearheaded this process by first obtaining a rapid approval for deflazacort in Macau – a special administrative region with a quicker drug registration mechanism. Macau [...]